Chemotherapy extravasation injury
Alerts and Notices
Important News & Links
Synopsis
Risk factors for extravasation include cannula placement into small, tortuous, or fragile veins, placement into a vein in a limb that has previously undergone radiation or chemotherapy, or the presence of an impaired venous circulation, lymphedema, Raynaud phenomenon, diabetes (type 1, type 2), or obesity. The degree of immunocompetence may modulate both the clinical severity of extravasation injuries and the therapeutic response to their management.
Cytotoxic agents are classified according to their potential to induce tissue damage if infiltration occurs. Neutrals, such as asparaginase and cyclophosphamide, typically do not cause any tissue reaction. Exfoliants, such as cisplatin and docetaxel, can lead to skin exfoliation. Inflammatory agents, such as methotrexate and fluorouracil, mainly trigger inflammation and discomfort without extensive tissue destruction. Irritants, such as carboplatin and etoposide, generate pain and local irritation. Vesicants are most destructive to tissue and may cause necrosis and ulceration with subsequent potential for nerve, muscle, ligament, and bone injury.
The extent of tissue injury from a vesicant depends on further factors, including the drug's concentration, the extravasated volume, the duration of exposure, and its ability to bind to DNA. Vesicants that bind to DNA, such as the anthracyclines (ie, doxorubicin), mitomycin, and mechlormetamine, have the greatest potential for tissue damage, as they affect replicating cells. Non-DNA-binding vesicants include vincristine, vinblastine, and vinorelbine (the vinca alkaloids). The anatomic sites at greatest risk for permanent damage from a vesicant include areas with scant subcutaneous tissue and a thinner dermis, such as the dorsal hands and feet, the antecubital fossae, and the ankles.
Codes
T14.8XXA – Other injury of unspecified body region, initial encounter
T50.905A – Adverse effect of unspecified drugs, medicaments and biological substances, initial encounter
SNOMEDCT:
264522001 – Extravasation of drug
Look For
Subscription Required
Diagnostic Pearls
Subscription Required
Differential Diagnosis & Pitfalls
Subscription Required
Best Tests
Subscription Required
Management Pearls
Subscription Required
Therapy
Subscription Required
Drug Reaction Data
Subscription Required
References
Subscription Required
Last Updated:11/09/2025
